Regen BioPharma Inc (RGBP)

[hardlesson]

'Revenues from continuing operations were $1,932,425,
for the quarter ended June 30,2021 and $27,425 for the same period ended 2020. The increase of approximately 6, 946% is attributable to $1,905,000 of revenue recognized during the quarter ended June 30, 2021 pursuant to a license granted to Oncology Pharma,Inc. Operating Income was $1,833,303 for the quarter ended June 30,2021 whereas Operating Loss was $16,336 for the same quarter ended 2020; an increase primarily attributable to $1,905,000 of revenue recognized during the quarter ended June 30,2021 pursuant to a license granted to Oncology Pharma, Inc'